Cystinosis requires lifelong cystine-depleting therapy; however, currently approved cysteamine products, Cystagon® and Procysbi®, are associated with frequent dosing, gastrointestinal intolerance, and ...

Veradermics is set to raise $200 million in an IPO to fund its novel extended-release oral minoxidil for pattern hair loss.

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

Market valued at $46.59B in 2024, projected 7.31% CAGR growth driven by bio-based adoption, detergent demand, and ...

With the rapid development of higher education and diversified funding sources, university budget management has become increasingly crucial in resource allocation and strategic implementation, while ...

Explore intellectual opportunities and connect with your community for inspiring results.

The Phase 1 clinical study is expected to enroll approximately 24 healthy adult volunteers. The primary objectives of the study are to characterize the pharmacokinetic release profile of the nalmefene ...

The Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, an oral formulation of arsenic trioxide, for the treatment of acute promyelocytic leukemia (APL), an aggressive ...

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyUnique sublingual formulation ...

Subcutaneous Saphnelo may offer people with lupus more convenient dosing with efficacy similar to the approved infusion version of the therapy, data show.

Stability is a critical factor in drug formulation, with implications for product quality, lifecycle management, and ...

SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration ...